The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib

The third-generation tyrosine kinase inhibitor (TKI) ponatinib shows activity against all common BCR-ABL1 single mutants, including the highly resistant BCR-ABL1-T315I mutant, improving outcome for patients with refractory chronic myeloid leukemia (CML). However, responses are variable, and causal b...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Blood
Hlavní autoři: Parker, Wendy T., Yeung, David T. O., Yeoman, Alexandra L., Altamura, Haley K., Jamison, Bronte A., Field, Chani R., Hodgson, J. Graeme, Lustgarten, Stephanie, Rivera, Victor M., Hughes, Timothy P., Branford, Susan
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Hematology 2016
Témata:
Clinical Trials and Observations
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4832506/
https://ncbi.nlm.nih.gov/pubmed/26773037
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-09-666214
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky